MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Patrick R. Griffin(The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology), Kevin R. Kelly(Keck Hospital of USC)
Cited by 190
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355